Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Key points from article – 1. Patients who relapse within 3 years of frontline FCR therapy have poor survival when treated with conventional salvage regimens. 2. Such patients are suitable for allogeneic stem cell transplantation and novel noncytotoxic therapies.